Vault-13

BRIDGEBIO ONCOLOGY THERAPEUT BBOT

COM NEW · Common Stock · CUSIP 107924102

42 institutional holders
56,812,37956.8m shares reported held*
$657.5mreported value*

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $11.57.

Biggest buyers

Cormorant Asset Management, LP New +17,878,594+17.9m
DEERFIELD MANAGEMENT COMPANY, L.P. New +4,885,446+4.9m
Omega Fund Management, LLC New +3,289,661+3.3m
WELLINGTON MANAGEMENT GROUP LLP New +2,961,263+3.0m
EcoR1 Capital, LLC New +2,823,126+2.8m
Alphabet Inc. New +2,823,126+2.8m
ENAVATE SCIENCES GP, LLC New +2,626,946+2.6m
CITADEL ADVISORS LLC New +2,538,141+2.5m
BlackRock, Inc. New +2,048,552+2.0m
NOVO HOLDINGS A/S New +1,961,317+2.0m

Biggest sellers

None

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Helix Holdings II LLC 13D · may seek influence filed 2025-08-13
Stated purposeItem 4 is hereby amended and supplemented as follows: As previously disclosed, on February 28, 2025, the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") entered into a Business Combination Agreement (as amended on June 20, 2025, the "Business Combination Agreement") with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, "Legacy BBOT"), and Helix II Merger Sub, Inc. ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, the Domestication of Helix as a Delaware corporation would occur, followed by the Merger of Merger Sub with and into Legacy BBOT. Prior to the Business Combination, Ms. Chen was the Chairwoman and Chief Executive Officer of the Issuer, a shareholder of the Issuer, and a shareholder of Leg… Full filing
22.6% 17.9m≈ $136.2m 2025-08-13
Chen Bihua 13D · may seek influence filed 2026-07-06
Stated purposeItem 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata distribution of shares to its members, (i) Fund III, a member of Sponsor, acquired 2,692,459 shares of Common Stock; (ii) Fund V, a member of Sponsor, acquired 1,704,862 shares of Common Stock; and (iii) Master Fund, a member of Sponsor, acquired 130,865 shares of Common Stock. Full filing
22.3% 17.9m≈ $136.2m 2026-07-06
BridgeBio Pharma LLC 13D · may seek influence new · filed 2025-08-18
Stated purposeThe Reporting Persons acquired the Shares for investment purposes in the ordinary course of business. Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P. McCormick, Ph.D., F.R.S., D.Sc., Chairman of Oncology and a member of the board of directors of BBIO, were appointed to serve as directors of the Issuer. As a result of their positions, Drs. Kumar and McCormick may, from time to time, engage in discussions with the Issuer's board of directors, management, or other stockholders regarding matters relating to the Issuer's business, operations, governance, strategy, or capital structure. These discussions may include, but are not limited to: (i) the acquisition or dispos… Full filing
17.5% new 13.9m≈ $105.8m 2025-08-18
BlackRock Portfolio Management LLC 13G · institution new · filed 2025-04-15 7.9% new 1.5m 2025-04-15
Flynn James E 13G · passive investor new · filed 2025-08-18 6.2% new 4.9m≈ $37.2m 2025-08-18
BC Global Opportunities IX LP 13G · passive investor new · filed 2025-09-03 5.5% new 4.4m≈ $33.3m 2025-09-03

Insider purchases and sales in Q3 2025

Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.

Officers and directors buying vs selling

Number of people, by quarter (10% owners not included)

BuyingSelling
101Q4 23: 0 buyingQ4 23: 0 sellingQ1 24: 1 buyingQ1 24: 0 sellingQ1 24Q2 24: 0 buyingQ2 24: 0 sellingQ3 24: 0 buyingQ3 24: 0 sellingQ3 24Q4 24: 0 buyingQ4 24: 0 sellingQ1 25: 0 buyingQ1 25: 0 sellingQ1 25Q2 25: 0 buyingQ2 25: 0 sellingQ3 25: 0 buyingQ3 25: 0 sellingQ3 25
Numbers
QuarterBuyingBoughtSellingSoldSold under a plan
Q4 20230—0——
Q1 20241$24.0m0——
Q2 20240—0——
Q3 20240—0——
Q4 20240—0——
Q1 20250—0——
Q2 20250—0——
Q3 20250—0——

None reported in Q3 2025.

Holders, Q3 2025

#ManagerLocationShares Value% of their portfolioChangeShares change
1 Cormorant Asset Management, LP 14.29% of their portfolio BOSTON, MA 17,878,59417.9m $207.0m $207.0m 14.29% New
2 DEERFIELD MANAGEMENT COMPANY, L.P. 0.87% of their portfolio New York, NY 4,885,4464.9m $56.6m $56.6m 0.87% New
3 Omega Fund Management, LLC 17.13% of their portfolio Boston, MA 3,289,6613.3m $38.1m $38.1m 17.13% New
4 WELLINGTON MANAGEMENT GROUP LLP 0.01% of their portfolio Boston, MA 2,961,2633.0m $34.3m $34.3m 0.01% New
5 EcoR1 Capital, LLC 1.57% of their portfolio San Francisco, CA 2,823,1262.8m $32.7m $32.7m 1.57% New
6 Alphabet Inc. 1.36% of their portfolio Mountain View, CA 2,823,1262.8m $32.7m $32.7m 1.36% New
7 ENAVATE SCIENCES GP, LLC 9.29% of their portfolio New York, NY 2,626,9462.6m $30.4m $30.4m 9.29% New
8 CITADEL ADVISORS LLC 0.02% of their portfolio MIAMI, FL 2,538,1412.5m $29.4m $29.4m 0.02% New
9 BlackRock, Inc. 0.00% of their portfolio New York, NY 2,048,5522.0m $23.7m $23.7m 0.00% New
10 NOVO HOLDINGS A/S 1.46% of their portfolio HELLERUP, G7 1,961,3172.0m $22.7m $22.7m 1.46% New
11 Paradigm Biocapital Advisors LP 0.64% of their portfolio NEW YORK, NY 1,866,1411.9m $21.6m $21.6m 0.64% New
12 ADAGE CAPITAL PARTNERS GP, L.L.C. 0.03% of their portfolio Boston, MA 1,487,6211.5m $17.2m $17.2m 0.03% New
13 EVENTIDE ASSET MANAGEMENT, LLC 0.20% of their portfolio Boston, MA 1,082,3621.1m $12.4m $12.4m 0.20% New
14 Laurion Capital Management LP 1.65% of their portfolio NEW YORK, NY 1,045,8001.0m $12.1m $12.1m 1.65% New
15 Octagon Capital Advisors LP 1.89% of their portfolio NEW YORK, NY 1,043,1101.0m $12.1m $12.1m 1.89% New
16 PRICE T ROWE ASSOCIATES INC /MD/ 0.00% of their portfolio BALTIMORE, MD 885,042885.0k $10.2m $10.2m 0.00% New
17 VANGUARD GROUP INC 0.00% of their portfolio Valley Forge, PA 647,599647.6k $7.5m $7.5m 0.00% New
18 Aisling Capital Management LP 1.43% of their portfolio NEW YORK, NY 564,625564.6k $6.5m $6.5m 1.43% New
19 GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio BOSTON, MA 541,602541.6k $6.3m $6.3m 0.00% New
20 ADAR1 Capital Management, LLC 0.57% of their portfolio AUSTIN, TX 501,228501.2k $5.8m $5.8m 0.57% New
21 SILVERARC CAPITAL MANAGEMENT, LLC 0.77% of their portfolio BOSTON, MA 457,414457.4k $5.3m $5.3m 0.77% New
22 ARMISTICE CAPITAL, LLC 0.15% of their portfolio NEW YORK, NY 412,000412.0k $4.8m $4.8m 0.15% New
23 MILLENNIUM MANAGEMENT LLC 0.00% of their portfolio NEW YORK, NY 369,563369.6k $4.1m $4.1m 0.00% New
24 Casdin Capital, LLC 0.27% of their portfolio New York, NY 282,312282.3k $3.3m $3.3m 0.27% New
25 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.00% of their portfolio SAN FRANCISCO, CA 279,350279.4k $3.2m $3.2m 0.00% New
26 Ikarian Capital, LLC 0.57% of their portfolio DALLAS, TX 245,231245.2k $2.8m $2.8m 0.57% New
27 STEMPOINT CAPITAL LP 0.44% of their portfolio NEW YORK, NY 186,614186.6k $2.2m $2.2m 0.44% New
28 STATE STREET CORP 0.00% of their portfolio BOSTON, MA 176,695176.7k $2.0m $2.0m 0.00% New
29 FMR LLC 0.00% of their portfolio BOSTON, MA 162,077162.1k $1.9m $1.9m 0.00% New
30 Sio Capital Management, LLC 0.38% of their portfolio NEW YORK, NY 130,628130.6k $1.5m $1.5m 0.38% New
31 TD Asset Management Inc 0.00% of their portfolio Toronto, A6 130,062130.1k $1.5m $1.5m 0.00% New
32 Woodline Partners LP 0.01% of their portfolio San Francisco, CA 103,707103.7k $1.2m $1.2m 0.01% New
33 MOORE CAPITAL MANAGEMENT, LP 0.02% of their portfolio NEW YORK, NY 100,000100.0k $1.2m $1.2m 0.02% New
34 BOOTHBAY FUND MANAGEMENT, LLC 0.03% of their portfolio NEW YORK, NY 96,55196.6k $1.1m $1.1m 0.03% New
35 NORTHERN TRUST CORP 0.00% of their portfolio CHICAGO, IL 95,95796.0k $1.1m $1.1m 0.00% New
36 UBS Group AG 0.00% of their portfolio ZURICH, V8 52,22652.2k $604.8k $604.8k 0.00% New
37 XTX Topco Ltd 0.01% of their portfolio LONDON, X0 23,38423.4k $270.8k $270.8k 0.01% New
38 China Universal Asset Management Co., Ltd. 0.00% of their portfolio SHANGHAI, F4 5,0005.0k $57.9k $57.9k 0.00% New
39 BANK OF AMERICA CORP /DE/ 0.00% of their portfolio CHARLOTTE, NC 1,3291.3k $15.4k $15.4k 0.00% New
40 MORGAN STANLEY 0.00% of their portfolio NEW YORK, NY 861861 $10.0k $10.0k 0.00% New
41 FNY Investment Advisers, LLC 0.00% of their portfolio NEW YORK, NY 100100 $1.0k $1.0k 0.00% New
42 ROYAL BANK OF CANADA 0.00% of their portfolio TORONTO, A6 1616 $0 $0 0.00% New